In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms

Vincent Trebosc 1*, Birgit Schellhorn1, Julian Schill1, Valentina Lucchini1,2, Jacqueline Bühler1, Marilyne Bourotte3, Jonathan J. Butcher1, Marc Gitzinger1, Sergio Lociuro1, Christian Kemmer1 and Glenn E. Dale1

1BioVersys AG, Basel, Switzerland; 2Biozentrum, University of Basel, Basel, Switzerland; 3BioVersys SAS, Lille, France

*Corresponding author. E-mail: vincent.trebosc@bioversys.com

Received 8 May 2020; accepted 3 August 2020

Background: Rifabutin, an oral drug approved to treat Mycobacterium avium infections, demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium enabled by rifabutin cellular uptake through the siderophore receptor FhuE.

Objectives: To determine rifabutin in vitro activity and resistance mechanisms in a large panel of A. baumannii isolates.

Methods: Two hundred and ninety-three carbapenem-resistant A. baumannii clinical isolates collected from Europe, the USA and Asia during 2017–19 were used for MIC determination. Sequencing/genotyping of fhuE, rpoB and arr-2 genes in isolates with elevated rifabutin MIC combined with genetic engineering and gene expression quantification was used to characterize rifabutin’s mode of action and resistance mechanisms.

Results: Rifabutin showed excellent activity on the strain panel, with an MIC 50/90 of 0.008/1 mg/L, and was superior to all other antibiotics tested, including colistin, tigecycline and cefiderocol (MIC 90 of 8 mg/L). Rifabutin remained active on resistant subpopulations, including strains resistant to the siderophore–drug conjugate cefiderocol (MIC 90 of 2 mg/L, n = 23). At least two independent resistance mechanisms were required to abolish rifabutin activity, which is in line with the dose-dependent mutational resistance frequency reaching 10^-9 at rifabutin concentrations at or above 2 mg/L.

Conclusions: This study demonstrated the potent activity of rifabutin against carbapenem-resistant A. baumannii. We propose that FhuE-mediated active uptake of rifabutin enables activity against rifampicin-resistant isolates. To achieve clinically meaningful strain coverage and to avoid rapid resistance development, rifabutin concentrations ≥2 mg/L are required, something rifabutin oral formulations cannot deliver.
This increased activity is mediated by cellular uptake of the antibiotic through the TonB-dependent siderophore receptor FhuE, which is up-regulated in RPMI supplemented with FCS but not in standard CA-MHB medium. Importantly, this novel in vitro activity correlated with excellent in vivo efficacy in murine systemic and lung infection models with A. baumannii. In this study we intended to determine the in vitro activity of rifabutin on a panel of recently isolated carbapenem-resistant A. baumannii (CRAB) isolates.

Materials and methods

Bacterial isolates

A. baumannii isolates (n = 293) used in this study were collected between 2017 and 2019 in various clinical laboratories from Europe (n = 144), the USA (n = 99) and Asia-West Pacific (n = 50) regions (JMI Laboratories, North Liberty, IA, USA). All the isolates were carbapenem resistant, and most of the isolates were from patients with bloodstream infection (n = 82), pneumonia (n = 174) or skin/soft tissue infection (n = 33) (Table S1, available as Supplementary data at JAC Online).

Susceptibility testing

Rifabutin MICs were determined using broth microdilution and agar dilution methods following the CLSI guidelines but using RPMI supplemented with 10% (v/v) FCS (IC-RPMI) as assay medium for broth microdilution and Mueller–Hinton agar (MHA) supplemented with 0.1 mM pyridoxal isonicotinoyl hydrazone (PIH) (IC-MHA) for agar dilution. MICs of the comparator antibiotics meropenem, ceftazidime, minocycline, colistin, tigecycline, tobramycin and cefiderocol were determined according to CLSI guidelines. The full panel of diverse A. baumannii strains (Table S3) was used in this study to assess the activity of rifabutin in RPMI supplemented with FCS, indicating that FhuE overexpression is a condition sufficient in CA-MHB to mediate rifabutin cellular uptake (Figure S2). Moreover, the expression of a FhuE variant carrying a V38P mutation (codon GTC to CCC) in the TonB box known to disrupt the interaction between FhuE and the energy transducer protein TonB, was not able to restore rifabutin susceptibility, indicating that the drug is highly selective towards FhuE transport (Figure S1). In contrast to those observed in RPMI supplemented with FCS, indicating that FhuE overexpression in a CA-MHB increased rifabutin activity to levels similar to those observed in RPMI supplemented with FCS, indicating that FhuE overexpression is a condition sufficient in CA-MHB to mediate rifabutin cellular uptake (Figure 2a, Figure S2). However, the activity of rifampicin and other known rifamycin antibiotics, including rifampicin CP4832, remained unchanged upon FhuE expression, indicating that FhuE is highly selective towards rifabutin transport (Figure S2). Moreover, the expression of a FhuE variant carrying a V38P mutation in the TonB box known to disrupt the interaction between FhuE and the energy transducer protein TonB, was not able to restore rifabutin susceptibility, indicating that the drug is actively transported via FhuE into A. baumannii (Figure 2a). Previous transcriptomic data have shown that reduction of iron-chelating activity in standard Mueller–Hinton medium enables active rifabutin cellular uptake through FhuE overexpression. Potential rifabutin activity observed in RPMI supplemented with 10% FCS is enabled by FhuE overexpression in this specific nutrient- and iron-depleted medium. In contrast, the standard CA-MHB MIC testing medium is a complex and rich medium that does not promote FhuE expression (Figure 1a). Plasmid-mediated expression of FhuE in CA-MHB increased rifabutin activity to levels similar to those observed in RPMI supplemented with FCS, indicating that FhuE overexpression is a condition sufficient in CA-MHB to mediate rifabutin cellular uptake (Figure 2a). However, the activity of rifampicin and other known rifamycin antibiotics, including rifampicin CP4832, remained unchanged upon FhuE expression, indicating that FhuE is highly selective towards rifabutin transport (Figure S2). Moreover, the expression of a FhuE variant carrying a V38P mutation in the TonB box known to disrupt the interaction between FhuE and the energy transducer protein TonB, was not able to restore rifabutin susceptibility, indicating that the drug is actively transported via FhuE into A. baumannii (Figure 2a).

Results
of skipped wells with MICs determined in CA-MHB supplemented with PIH or with other iron chelators (apo-transferrin, 2,2-bipyridyl and deferiprone) (Figure S3). The characterization of clones from MIC with skipped wells demonstrated that this phenomenon results from mutations in \( fhuE \) leading to a disrupted rifabutin uptake (Table S4). Specific uptake disruption \textit{in vitro} was previously reported for the antibiotic fosfomycin, for which agar dilution MIC is the only approved method allowing robust MIC determination; according to CLSI guidelines, broth microdilution should not be performed.\textsuperscript{7,12} Therefore, we determined rifabutin agar dilution MICs on MHA supplemented with 0.1 mM PIH and confirmed that PIH addition to MHA triggers a \( fhuE \)-dependent uptake of rifabutin (Figure 1c). The results obtained on MHA supplemented with 0.1 mM PIH (white) on WT \( A.\ baumannii \) strains and their \( \Delta fhuE \) mutants.

### Figure 1

Quantification of \( fhuE \) expression level and rifabutin activity against \( A.\ baumannii \). (a) \( A.\ baumannii \) HUMC1 \( fhuE \) transcript levels were determined in different media by quantitative real-time PCR and normalized to the \( fhuE \) expression of the strain grown in CA-MHB. CA-MHB and RPMI media were supplemented with 0.1 mM pyridoxal isonicotinoyl hydrazone (PIH) or 10% (v/v) FCS, respectively. (b) Rifabutin activity on \( A.\ baumannii \) HUMC1 determined in CA-MHB supplemented with PIH. (c) Rifabutin activity determined in RPMI supplemented with 10% (v/v) FCS (black) and MHA supplemented with 0.1 mM PIH (white) on WT \( A.\ baumannii \) strains and their \( \Delta fhuE \) mutants.

### Figure 2

Activity of rifabutin (black bars) and rifampicin (white bars) upon plasmid-mediated expression of (a) different FhuE variants determined in CA-MHB medium and (b) Arr-2 determined in RPMI supplemented with 10% FCS. \( A.\ baumannii \) ATCC-17978 was used as host strain; gene expression from plasmids was induced with 1 mM IPTG, and a plasmid that did not encode \( fhuE \) or \( arr-2 \) was used as control. *MIC >32 mg/L.

Rifabutin shows excellent activity on 293 CRAB isolates

A panel of 293 CRAB clinical isolates collected between 2017 and 2019 from Europe (\( n = 144 \)), the USA (\( n = 99 \)) and Asia-West Pacific (\( n = 50 \)) regions was used for rifabutin MIC determination. Rifabutin MICs were determined by broth microdilution and agar dilution methods in IC-RPMI and IC-MHA, respectively (Table S1). Rifabutin showed excellent activity in both testing methods, with an MIC\(_{50}/\text{MIC}_{90} \) of 0.002/2 mg/L and 0.008/1 mg/L using IC-RPMI and IC-MHA, respectively (Figure 3a). There was little difference
between testing methods in the overall susceptibility of the isolates. However, for the isolates with a very low MIC (<0.008 mg/L), a one-dilution shift towards lower MIC in IC-RPMI was observed, which may reflect the nutrient-limited conditions of this medium (Figure 3a). In addition, rifabutin activity was consistent across regions and infection types, with only a one-dilution MIC90 shift for isolates from the USA or from soft/skin tissue infections (MIC90 of 2 mg/L) (Table 1).

Rifabutin was superior to all comparator antibiotics tested, including colistin, tigecycline and cefiderocol (Figure 4, Table 2). Overall, rifabutin activity was not affected by resistance to specific antibiotics as the rifabutin MIC50/MIC90 remained stable on the different antibiotic-resistant subpopulations (Table 3). Importantly, there was no cross-resistance between rifabutin and cefiderocol despite both drugs employing bacterial iron transport mechanisms for efficient cellular uptake.

Inactive rifabutin cellular uptake confers elevated rifabutin MIC in A. baumannii clinical isolates

Further analysis of the rifabutin MICs revealed three A. baumannii subpopulations with distinct rifabutin susceptibilities, population 1 (Pop1, MICs <0.125 mg/L, 72%), population 2 (Pop2, MICs ≥0.125 to <16 mg/L, 27%) and population 3 (Pop3, MICs ≥16 mg/L, 1%)

Figure 3. Comparison of the efficacy of rifabutin against 293 carbapenem-resistant clinical isolates of A. baumannii in two different media. (a) Cumulative susceptibility and (b) MIC distribution of rifabutin determined in IC-RPMI and IC-MHA.
The DNA sequence of the TonB-dependent siderophore receptor \textit{fhuE}, responsible for rifabutin cellular uptake, was altered in 85% (\(n = 70\)) of the clinical isolates from Pop2 and Pop3 (\(n = 82\)) (Table 4, Table S6). Single mutation events inactivating \textit{FhuE} were found in 50% (\(n = 35\)) of the strains with disrupted rifabutin uptake, including transposon insertions, nucleotide deletions/insertions and early stop codon mutations. The other 35 strains encoded a distinct \textit{FhuE} variant (\textit{FhuELAC-4}) with only 59% amino acid identity to the \textit{FhuE} encoded in the reference strain \textit{HUMC1} (\textit{FhuEHUMC1}).

Chromosomal replacement of \textit{fhuELAC-4} by the \textit{fhuEHUMC1} allele in the LAC-4 strain restored the potent activity of rifabutin (Figure 5a). In contrast, plasmid-mediated expression of \textit{FhuELAC-4} did not improve rifabutin activity in CA-MHB, confirming that \textit{FhuELAC-4} is unable to transport rifabutin (Figure 2a, Figure S1).

To determine whether \textit{FhuELAC-4} was still active in transporting siderophores, we evaluated the ability of siderophores to restore the growth of the \textit{A. baumannii} ATCC 17978 mutant deleted for endogenous acinetobactin biosynthesis and expressing \textit{FhuEHUMC1} or \textit{FhuELAC-4} in iron-limiting conditions, as previously described. Both \textit{FhuEHUMC1} and \textit{FhuELAC-4} variants restored growth in the presence of siderophores, indicating that despite their sequence divergence both \textit{FhuE} variants can transport siderophores (Figure 6). The \textit{FhuELAC-4} variant may be derived from \textit{Acinetobacter pittii},

### Table 1. Cumulative susceptibility to rifabutin determined in IC-MHA against all \textit{A. baumannii} isolates or by region and infection type

| Rifabutin MIC (mg/L) | Cumulative percentage of isolates (%) super| Total (\(n = 293\)) | Europe (\(n = 144\)) | USA (\(n = 99\)) | Asia (\(n = 50\)) | BSI (\(n = 82\)) | HAP (\(n = 174\)) | SSI (\(n = 33\)) |
|---------------------|----------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| 0.0005 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0.001 | 1 | 2 | 0 | 2 | 0 | 2 | 0 | 0 |
| 0.002 | 16 | 18 | 10 | 22 | 17 | 17 | 9 | 0 |
| 0.004 | 40 | 43 | 30 | 52 | 49 | 37 | 9 | 0 |
| 0.008 | 67 | 75 | 51 | 76 | 83 | 62 | 52 | 52 |
| 0.016 | 71 | 81 | 54 | 80 | 84 | 68 | 52 | 52 |
| 0.031 | 72 | 81 | 54 | 80 | 84 | 69 | 52 | 52 |
| 0.063 | 72 | 82 | 54 | 80 | 84 | 69 | 52 | 55 |
| 0.125 | 73 | 83 | 55 | 80 | 84 | 70 | 55 | 55 |
| 0.25 | 74 | 83 | 56 | 82 | 84 | 72 | 55 | 55 |
| 0.5 | 76 | 86 | 59 | 84 | 87 | 74 | 61 | 61 |
| 1 | 91 | 94 | 83 | 98 | 96 | 90 | 79 | 79 |
| 2 | 97 | 98 | 94 | 98 | 98 | 91 | 91 | 91 |
| 4 | 99 | 100 | 98 | 98 | 99 | 99 | 99 | 99 |
| 8 | 99 | 100 | 98 | 98 | 99 | 99 | 99 | 99 |
| 16 | 99 | 100 | 99 | 98 | 99 | 99 | 100 | 100 |
| 32 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |

BSI, bloodstream infection; HAP, hospital-acquired infection; SSI, soft/skin tissue infection.

\(\text{MIC}_{90}\) values are shown in bold for each MIC distribution.

(Figure 3b, Table S5). The DNA sequence of the TonB-dependent siderophore receptor \textit{fhuE}, responsible for rifabutin cellular uptake, was altered in 85% (\(n = 70\)) of the clinical isolates from Pop2 and Pop3 (\(n = 82\)) (Table 4, Table S6). Single mutation events inactivating \textit{FhuE} were found in 50% (\(n = 35\)) of the strains with disrupted rifabutin uptake, including transposon insertions, nucleotide deletions/insertions and early stop codon mutations. The other 35 strains encoded a distinct \textit{FhuE} variant (\textit{FhuELAC-4}) with only 59% amino acid identity to the \textit{FhuE} encoded in the reference strain \textit{HUMC1} (\textit{FhuEHUMC1}).

Chromosomal replacement of \textit{fhuELAC-4} by the \textit{fhuEHUMC1} allele in the LAC-4 strain restored the potent activity of rifabutin (Figure 5a). In contrast, plasmid-mediated expression of \textit{FhuELAC-4} did not improve rifabutin activity in CA-MHB, confirming that \textit{FhuELAC-4} is unable to transport rifabutin (Figure 2a, Figure S1). To determine whether \textit{FhuELAC-4} was still active in transporting siderophores, we evaluated the ability of siderophores to restore the growth of the \textit{A. baumannii} ATCC 17978 mutant deleted for endogenous acinetobactin biosynthesis and expressing \textit{FhuEHUMC1} or \textit{FhuELAC-4} in iron-limiting conditions, as previously described. Both \textit{FhuEHUMC1} and \textit{FhuELAC-4} variants restored growth in the presence of siderophores, indicating that despite their sequence divergence both \textit{FhuE} variants can transport siderophores (Figure 6). The \textit{FhuELAC-4} variant may be derived from \textit{Acinetobacter pittii},

![Figure 4. Cumulative susceptibility of rifabutin and comparator antibiotics against a panel of 293 carbapenem-resistant \textit{A. baumannii}. Rifabutin MIC was determined in IC-MHA, whereas the MICs of meropenem, ceftazidime, minocycline, tigecycline, colistin, tobramycin and cefiderocol were determined according to CLSI guidelines.](image-url)
which encodes a FhuE variant with 96% amino acid identity to FhuE^{LAC-4}, while the other pathogenic Acinetobacter species (namely A. nosocomialis, A. lactucae and A. seifertii) encode FhuE variants similar to FhuE^{HUMC1} (93%–97% amino acid identity). In addition, phylogenetic analysis revealed that each A. baumannii FhuE variant seems to be conserved in specific clonal lineages (Table S7). The FhuE^{HUMC1} variant is conserved in international clone (IC) 1 and IC2 strains, representing global clonal lineages.

Table 2. Overview of antimicrobial susceptibility of 293 clinical A. baumannii isolates and clinical classification according to EUCAST and CLSI guidelines

| Antimicrobial agent | MIC_{50} (mg/L) | MIC_{90} (mg/L) | EUCAST \(^a\) | CLSI \(^b\) |
|---------------------|-----------------|-----------------|---------------|---------------|
| Rifabutin \(^c\)    | 0.008           | 1               | %S            | %R            | %S            | %R            | %S            | %I            | %R            |
| Meropenem           | >32             | >32             | 0             | 100.0         | 0             | 0.3           | 99.7          |
| Ceftazidime         | >32             | >32             | –             | –             | 6.8           | 4.5           | 88.7          |
| Minocycline         | 4               | 32              | –             | –             | 55.3          | 14.7          | 30.0          |
| Tigecycline         | 2               | 8               | –             | –             | –             | –             | –             |
| Colistin            | 0.25            | 8               | 84.6          | 15.4          | 84.6          | –             | 15.4          |
| Tobramycin          | >16             | >16             | 38.2          | 61.8          | 38.2          | 3.4           | 58.4          |
| Cefiderocol         | 1               | 8               | –             | –             | 87.7          | 4.4           | 7.8           |

\(^5\) susceptible; \(^I\) intermediate; \(^R\) resistant.  
\(^a\) EUCAST Clinical breakpoints version 9.0.34  
\(^b\) CLSI document M100-Ed30.7  
\(^c\) Rifabutin MIC determined on IC-MHA.

Table 3. Rifabutin shows strong activity against A. baumannii subpopulations resistant to different antibiotics

| Resistant subpopulation | No. of isolates | Rifabutin MIC_{50} (mg/L) \(^a\) | Rifabutin MIC_{90} (mg/L) \(^a\) |
|-------------------------|-----------------|----------------------------------|----------------------------------|
| Minocycline ≥16 mg/L    | 88              | 0.008                            | 1                                |
| Colistin ≥2 mg/L        | 45              | 0.008                            | 1                                |
| Tigecycline ≥2 mg/L     | 147             | 0.008                            | 1                                |
| Tobramycin ≥16 mg/L     | 171             | 0.008                            | 1                                |
| Cefiderocol ≥16 mg/L    | 23              | 0.008                            | 2                                |

\(^a\) Rifabutin MICs determined on IC-MHA were used for calculations.

Table 4. Overview of the resistance mechanisms (based on FhuE) in relation to rifabutin and rifampicin activity on the 82 strains that belong to Pop2 and Pop3 rifabutin susceptibility subpopulations

| FhuE mutations | No. of strains | MIC range (mg/L) | Rifabutin \(^a\) | Rifampicin | Additional resistance mechanisms (RpoB/Arr-2) |
|----------------|----------------|------------------|------------------|------------|---------------------------------------------|
| WT             | 2              | 0.125–1          | 8                |            | RpoB LS42F                                  |
|                | 4              | 0.125–1          | >32              |            | RpoB HS355                                  |
|                | 1              | >32              | >32              |            | RpoB HS355                                  |
|                | 3              | 0.5–4            | >32              |            | RpoB HS35C                                  |
|                | 2              | 0.25–0.5         | >32              |            | Arr-2                                       |
| LAC-4          | 33             | 0.5–4            | 1–8              |            | none                                        |
|                | 1              | 16               | >32              |            | RpoB HS35Q                                  |
|                | 1              | >32              | >32              |            | Arr-2                                       |
| Disrupted \(^b\)| 34             | 0.25–4           | 4–16             |            | none                                        |
|                | 1              | 4                | >32              |            | RpoB HS35Q                                  |

\(^a\) Rifabutin MIC determined on IC-MHA.  
\(^b\) FhuE disruption due to transposon insertion, nucleotide deletion/insertion or an early stop codon. More information can be found in Table S6.  

which encodes a FhuE variant with 96% amino acid identity to FhuE^{LAC-4}, while the other pathogenic Acinetobacter species (namely A. nosocomialis, A. lactucae and A. seifertii) encode FhuE variants similar to FhuE^{HUMC1} (93%–97% amino acid identity). In addition, phylogenetic analysis revealed that each A. baumannii FhuE variant seems to be conserved in specific clonal lineages (Table S7). The FhuE^{HUMC1} variant is conserved in international clone (IC) 1 and IC2 strains, representing global clonal lineages.
with IC2 being the most prevalent worldwide. In contrast, FhuELAC-4 is conserved in strains from IC5, which is a pan-American clonal lineage. This is in accordance with our strain panel where 80% of the strains encoding the FhuE LAC-4 variant were isolated from the USA (Table S6).

Rifabutin overcomes RpoB mutations and Arr-2 expression conferring rifampicin resistance in A. baumannii clinical isolates

Mutations in the DNA-dependent RNA polymerase β-subunit (RpoB) and expression of the arr-2 gene coding for rifampicin ADP-ribosyltransferase are mechanisms that confer resistance to rifamycin antibiotics, and those resistance mechanisms have previously been identified in A. baumannii. Mutations in RpoB RRDR cluster I and II were identified in 86% (n = 19) of the strains with an elevated rifampicin MIC (MIC >32 mg/L, n = 22) while the other 14% (n = 3) of the strains with an elevated rifampicin MIC encoded the arr-2 gene (Table 5, Table S8).

The most frequent RpoB mutation, found in 16 isolates (73%), was the substitution of a histidine at position 535 by a glutamine (n = 8), leucine (n = 5) or cystine (n = 3). Among the isolates with RpoB mutations, nine strains belonged to Pop1 rifabutin susceptibility (MICs <0.125 mg/L), eight strains belonged to Pop2 (MICs 0.125 to <16 mg/L) and only two strains belonged to Pop3 (MICs ≥16 mg/L), suggesting that most RpoB mutations present in A. baumannii clinical isolates do not abolish rifabutin activity, in contrast to rifampicin loss of activity. Rifabutin uptake deletion in the Pop1 strains carrying RpoB mutations converted them to Pop3 strains, suggesting that potent rifabutin activity on RpoB mutants is due to FhuE-mediated active transport of rifabutin (Figure 5b).

Interestingly, the two Pop3 strains (BV667 and BV788) carried...
RpoB mutations identical to other Pop1 and Pop2 strains, suggesting that an additional mechanism must be involved in the elevated rifabutin MIC of these two strains (Table 5). The strain BV788 encoded a FhuELAC-4 variant in addition to the RpoB H535Q mutation, and chromosomal replacement of \textit{fhuELAC-4} by \textit{fhuEHUMC1} in this strain confirmed that rifabutin overcomes resistance conferred by this RpoB mutation (Figure 5a). The second Pop3 strain (BV667) carried an RpoB H535L mutation but did not encode additional \textit{arr-2} or \textit{fhuE} disruption, indicating that another rifabutin resistance mechanism may exist. The entire \textit{rpoB} gene of BV667 was sequenced to rule out additional mutations outside RRDR clusters, and the induction of \textit{fhuE} expression upon iron chelation was confirmed (Figure S4).

Among the \textit{arr-2}-expressing isolates, two strains belonged to rifabutin susceptibility Pop2 and only one strain belonged to Pop3 (Table 5). The Pop3 strain encoded a FhuELAC-4 variant in addition to the \textit{arr-2} gene. Deletion of \textit{fhuE} in a strain carrying \textit{arr-2} (BV840) as its only resistance mechanism, as well as plasmid-mediated \textit{arr-2} expression, demonstrated that the \textit{arr-2} resistance mechanism alone does not abolish rifabutin activity, in contrast to loss of rifampicin activity (Figures 2b and 5b).

The frequency of mutational resistance of \textit{A. baumannii} strains to rifabutin is dose dependent, reaching $10^{-9}$ at drug concentrations at or above 2 mg/L.

The mutational FoR to rifabutin determined on the Pop1 strain UNT091-1 ranged from $10^{-5}$ to $10^{-6}$ with rifabutin concentrations up to 1 mg/L and decreased to $10^{-9}$ at rifabutin concentrations at or above 2 mg/L (Table 6). No difference was observed between rifabutin FoR determined on IC-MHA and IC-RPMI agar plates. This dose-dependent FoR suggests that a multistep mutational process is required to acquire full rifabutin resistance (MIC >32 mg/L), which is in accordance with the identification of at least two independent resistance mechanisms in Pop3 clinical isolates (Tables 4 and 5). In addition, the median FoR determined at 4-fold MIC on rifabutin activity and resistance in \textit{A. baumannii} JAC

| Table 5. Overview of the resistance mechanisms (based on RpoB) in relation to rifabutin and rifampicin activity on the 22 strains with rifampicin MIC above 32 mg/L |
| RpoB mutations | No. of strains | Rifabutin$^a$ | Rifampicin | Additional resistance mechanisms (FhuE/Arr-2) |
|-----------------|----------------|--------------|------------|---------------------------------|
| WT | 2 | 0.25-0.5 | >32 | Arr-2 |
| 1 | >32 | >32 | FhuE LAC-4 and Arr-2 |
| I581M | 1 | 0.016 | >32 | none |
| S583L | 1 | 0.06 | >32 | none |
| NS57D | 1 | 0.008 | >32 | none |
| HS35Q | 6 | 0.008-0.016 | >32 | FhuE disruption |
| 1 | 4 | >32 | FhuE LAC-4 |
| 1 | 16 | >32 | none |
| HS35L | 4 | 0.125-1 | >32 | none |
| 1 | >32 | >32 | none |
| H535C | 3 | 0.5-4 | >32 | none |

More information can be found in Table S8.

$^a$Rifabutin MIC determined on IC-MHA.

| Table 6. \textit{A. baumannii} UNT091-1 mutational resistance frequencies towards rifabutin |
| Rifabutin concentration | Frequency of resistance | Rifabutin MIC (mg/L)$^a$ |
|--------------------------|-------------------------|--------------------------|
| UNT091-1 wildtype | - | 0.001 |
| 0.02 mg/L | $1.1 \times 10^{-5}$ | 1 |
| 0.2 mg/L | $7.7 \times 10^{-6}$ | 1 |
| 0.5 mg/L | $7.5 \times 10^{-6}$ | ND |
| 1 mg/L | $6.0 \times 10^{-6}$ | ND |
| 2 mg/L | $4.2 \times 10^{-9}$ | >32 |
| 20 mg/L | $4.3 \times 10^{-9}$ | >32 |

ND, not determined.

$^a$Rifabutin MIC determined in IC-RPMI.

10 Pop2 strains was $6.7 \times 10^{-9}$, indicating that intermediate resistance levels do not affect the FoR to rifabutin (Table S9). Finally, FoRs to rifabutin were 1 log lower than FoRs to meropenem and minocycline and in the same range as the FoR to tobramycin (Table S10). Our data suggest that rifabutin resistance development in \textit{A. baumannii} is low at or above 2 mg/L, and similar or better than resistance development to standard of care antibiotics.

**Discussion**

Rifabutin demonstrated potent in vitro activity on clinical CRAB isolates collected between 2017 and 2019 from three different continents. Rifabutin was equally active across geographical regions and infection types, including bloodstream infection and hospital-acquired pneumonia, with an MIC$_{90}$ of 1–2 mg/L. The clonal nature of \textit{A. baumannii} may lead to a considerable number of identical strains derived from clinical outbreaks. However, the tested isolates were collected from 72 different clinical sites within 22 different countries to reduce a potential bias of the study. In terms of MIC$_{90}$, rifabutin was superior to all tested comparator
Figure 7. Model for rifabutin and rifampicin mode of action and resistance mechanisms in A. baumannii. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
antibiotics including colistin and ceftazidime. Notably, rifabutin maintained potency against A. baumannii subpopulations resistant to different classes of antibiotics, such as strains resistant to colistin, minocycline, tetracycline, and ceftazidime. The absence of cross-resistance between rifabutin and the siderophore–drug conjugate ceftazidime suggests that these two drugs use different iron uptake systems for cellular influx. Cefiderocol transport systems have been identified in E. coli (CirA and Fiu) and in Pseudomonas aeruginosa (PiuA) but not in A. baumannii. Nevertheless, cefiderocol resistance in A. baumannii is mainly due to the expression of specific β-lactamases, justifying the absence of cross-resistance to rifabutin.

Rifabutin MICs determined in IC-MHA medium were consistent with MICs determined in IC-RPMI, in which the potent activity of rifabutin was originally observed. The rifabutin broth microdilution MIC method using IC-CA-MHB (CA-MHB supplemented with 0.1 mM PIH) medium sometimes led to skipped wells due to rifabutin uptake mutations. Interestingly, this phenomenon was observed only with highly susceptible strains (Pop1) and at rifabutin concentrations below 2 mg/L, which is in line with the low FoR observed at or above 2 mg/L. Skipped wells in the broth microdilution MIC method translates in agar dilution MIC tests to single colony growth, which, according to the CLSI, should be disregarded when reading agar dilution MIC endpoints. Therefore, the agar dilution MIC method using IC-MHA medium allows robust determination of rifabutin activity on all A. baumannii strains while the broth microdilution MIC method using IC-CA-MHB medium allows robust determination of rifabutin MICs only in Pop2 and Pop3 strains (MIC ≥ 0.125 mg/L).

The trimodal MIC distribution and the dose-dependent FoR suggested that resistance to rifabutin is a multistep process. This was confirmed with the characterization of rifabutin resistance mechanisms in the Pop2 and Pop3 strains. All the strains with rifabutin MIC at or above 0.125 mg/L had disrupted rifabutin uptake (FhuE), a mutant rifabutin target (RpoB) or a rifabutin inactivation enzyme (Arr-2). Notably, we demonstrated that loss of rifabutin activity (MIC > 32 mg/L) was conferred by a combination of at least two independent resistance mechanisms in clinical strains. In contrast, RpoB mutations or the presence of the Arr-2 inactivation enzyme led to loss of rifampicin activity (MIC > 32 mg/L). It has been described that rifabutin retains activity in the case of specific RpoB mutations that confer rifampicin resistance in Mycobacterium tuberculosis. However, disruption of rifabutin uptake in A. baumannii Pop1 strains carrying RpoB mutations decreases rifabutin activity to the same extent as rifampicin. Moreover, Arr-2 expression has been shown to confer equal resistance to rifampicin and rifabutin. Altogether these data suggest that rifabutin overcomes RpoB mutation and Arr-2 expression resistance mechanisms because it is actively transported into A. baumannii. We propose a rifabutin mechanism of action in which, as in contrast to rifampicin passive diffusion, FhuE-mediated rifabutin active transport creates a high concentration of drug at the site of action, enabling activity against target mutation and enzymatic inactivation resistance mechanisms (Figure 7). The identification of one Pop3 strain only carrying the RpoB H535L mutation, which is also present in several Pop2 strains, suggests that rifabutin resistance mechanisms not identified in this study may exist in clinical isolates.

TonB-dependent transporter (TBDT)-mediated uptake of the rifamycin derivative CGP 4832 has previously been described. Rifamycin CGP 4832 is actively transported across the outer membrane of E. coli by the siderophore receptor FhuA, but we demonstrated that it is not transported by A. baumannii FhuE. Conversely, rifabutin seems not to be transported by any TBDT from E. coli, Klebsiella pneumoniae and P. aeruginosa, as rifabutin does not show potent activity against those Gram-negative species. In addition, none of the commercially available rifamycin antibiotics was transported by A. baumannii FhuE. These results are in line with TBDT high substrate specificity, as TBDT-mediated transport requires specific substrate binding to activate allosteric conformational transition of the transporter leading to the recruitment of the TonB energy transducing machinery through the so-called TonB box of the TBDT. It has been demonstrated that rifamycin CGP 4832 is transported in a TonB-dependent manner, and a crystallographic study suggested that the binding of CGP 4832 to FhuA induces an allosteric transition allowing physical interaction between TonB and the FhuA TonB box. In the same manner, we demonstrated that rifabutin is transported by FhuE in a TonB-dependent manner, suggesting that rifabutin binding to FhuE is required to induce active transport through the A. baumannii outer membrane.

Our in vitro data on rifabutin activity and mutational resistance frequency suggest that rifabutin concentrations must be at or above 2 mg/L to be effective against A. baumannii infections and to avoid rapid resistance development. Rifabutin is available on the market as an oral drug with a maximum recommended dose of 300 mg/day. However, pharmacokinetic studies have shown that maximum concentrations of rifabutin remained below 1 mg/L with a daily dose up to 600 mg. Therefore, use of oral rifabutin in the treatment of A. baumannii infections will have only limited efficacy and would certainly lead to rapid development of resistance. In an attempt to overcome these limitations, BioVersys AG has developed an intravenous formulation of rifabutin (BV100) for the treatment of A. baumannii infections that have limited treatment options, including hospital- and ventilator-associated pneumonia and bloodstream infections, for patient populations where an intravenous formulation is required.

Acknowledgements

JMI Laboratories provided the panel of 293 carbapenem-resistant A. baumannii strains used in this study.

Funding

This study was supported by internal funding. V.L. was supported by the European Commission via the International Training Network Train2Target (721484).

Transparency declarations

All authors are employees and own shares or stock options of BioVersys AG.
**Supplementary data**

Figures S1 to S4 and Tables S1 to S10 are available as Supplementary data at JAC Online.

**References**

1. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1–12.

2. Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc 2015; 90: 395–403.

3. Taccconelli E, Carrara E, Savoldi A et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018; 18: 318–27.

4. Craboy J, Catherinot E, Veziris N et al. Rifabutin: where do we stand in 2016? J Antimicrob Chemother 2016; 71: 1759–71.

5. Vaara M. Comparative activity of rifabutin and rifampicin against Gram-negative bacteria that have damaged or defective outer membranes. J Antimicrob Chemother 1993; 31: 799–801.

6. Luno B, Trebosch V, Lee B et al. A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii. Nat Microbiol 2020; doi:10.1038/s41564-020-0737-6.

7. CLSI. Performance Standards for Antimicrobial Susceptibility Testing—30th Edition: M07-A10, 2015.

8. Trebosch V, Gertenmann S, Royet K et al. A novel genome-editing platform for drug-resistant Acinetobacter baumannii reveals an AdelR-unrelated tigecycline resistance mechanism. Antimicrob Agents Chemother 2016; 60: 7263–71.

9. Fundahsi T, Tanabe T, Mihara K et al. Development of rifamycin cross-resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2016; 71: 1759–71.

10. Cadieux N, Bradbeer C, Kadner RJ. Sequence changes in the ton box region of BtuB affect its transport activities and interaction with TonB protein. BMC Genomics 2011; 12: 126.

11. Cadieux N, Bradbeer C, Kadner RJ. Sequence changes in the ton box region of BtuB affect its transport activities and interaction with TonB protein. BMC Genomics 2011; 12: 126.

12. Ballester-Téllez M, Docobo-Pérez F, Rodriguez-Martinez JM et al. Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae. Clin Microbiol Infect 2017; 23: 325–31.

13. Ito A, Nishikawa T, Matsumoto S et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2016; 60: 7396–401.

14. Higgins PG, Dammhahn C, Hackel M et al. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 223–8.

15. Giannouli M, Di Popolo A, Durante-Mangoni E et al. Molecular epidemiology and mechanisms of rifampicin resistance in Acinetobacter baumannii isolates from Italy. Int J Antimicrob Agents 2012; 39: 58–63.

16. Baysarowich J, Koteva K, Hughes DW et al. Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr. Proc Natl Acad Sci USA 2008; 105: 4886–91.

17. Fournier P-E, Vallenet D, Barbe V et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006; 2: e7.

18. Houang ETS, Chu Y-W, Lo W-S et al. Epidemiology of rifampin ADP-ribosyltransferase (arr-2) and metallo-β-lactamase (blaIMP-4) gene cassettes in class 1 integrons in Acinetobacter strains isolated from blood cultures in 1997 to 2000. Antimicrob Agents Chemother 2003; 47: 1382–90.

19. Ito A, Sato T, Ota M et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 2018; 62: e01454–17.

20. Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria. Clin Infect Dis 2019; 69: S544–51.

21. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition: M07-A10, 2015.

22. Yang B, Koga H, Ohno H et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998; 42: 621–8.

23. Williams DL, Spring L, Collins L et al. Contribution of rpoB mutations to development of rifampicin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1853–7.

24. Causagoul C, Karaca-Derici Y, Bigic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004; 10: 662–5.

25. Farhat MR, Sixsmith J, Calderon R et al. Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother 2019; 74: 1477–83.

26. Whitfield MG, Warren RM, Mathys V et al. The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. J Antimicrob Chemother 2018; 73: 2667–74.

27. Jing W, Pang Y, Zong Z et al. Rifabutin resistance associated with double mutations in rpoB gene in Mycobacterium tuberculosis isolates. Front Microbiol 2017; 8: 1768.

28. Rukasho I, Said HM, Omar SV et al. Correlation of rpoB mutations with minimal inhibitory concentration of rifampin and rifabutin in Mycobacterium tuberculosis in an HIV/AIDS endemic setting, South Africa. Front Microbiol 2016; 7: 1947.

29. Wehrli W, Zimmermann W, Kump W et al. CGP 4832, a new semi-synthetic rifamycin derivative highly active against some Gram-negative bacteria. J Antimicrob Chemother 1987; 40: 1733–9.

30. Pugsley AP, Zimmerman W, Wehrli W. Highly efficient uptake of a rifamycin derivative via the FhuA–TonB-dependent uptake route in Escherichia coli. J Gen Microbiol 1987; 133: 3505–11.

31. Ferguson AD, Kauding J, Walker G et al. Active transport of an antibiotic rifamycin derivative by the outer-membrane protein FhuA. Structure 2001; 9: 707–16.

32. Noinaj N, Guillier M, Barnard TJ et al. TonB-dependent transporters: regulation, structure, and function. Annu Rev Microbiol 2010; 64: 43–60.

33. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996; 22 Suppl 1: S15–21; discussion S21–2.

34. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020.